 Subjects were admitted to the Clinical Pharmacology Unit CPU on Day -1 Visit 2, and the randomized treatment period began on Day 1 following a 10-hour minimum overnight fast. Subjects were randomly assigned to treatment with CD24Fc or placebo as a single dose. Subjects remained confined until the morning of Day 4. 